Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study

被引：0
|
作者：
El Saadany, Tamer
Petrausch, Ulf
Mora, Alfonso Rojas
Winder, Thomas
Renner, Christoph
Benda, Magdalena
Reimann, Patrick
Froesch, Patrizia
Jakob, Andreas
Daza, Adriana Clavijo
Mueller, Gisela
Von Moos, Roger Anton Fredy
Mark, Michael Thomas
机构：
[1] Kantonsspital Graubuenden, Div Hematol Oncol, Chur, Switzerland
[2] Hirslanden Zurich, Div Hematol Oncol, Zurich, Switzerland
[3] Swiss Grp Clin Canc Res SAKK, Competence Ctr, Bern, Switzerland
[4] Landeskrankenhaus Feldkirch, Internal Med 2, Feldkirch, Austria
[5] Swiss Tumor Inst, Zurich, Switzerland
[6] Hosp Feldkirch, Div Hematol Oncol, Feldkirch, Austria
[7] Hosp Feldkirch, Div Hematol Oncol, Dept Internal Med 2, Feldkirch, Austria
[8] Ente Osped Cantonale EOC, Oncol Inst Southern Switzerland IOSI, Bellinzona, Switzerland
[9] Tumor Zentrum Aarau, Aarau, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6619
引用
收藏
页数：1
相关论文
共 50 条
  • [21] COVID-19 vaccination status and clinical outcomes in solid cancer patients treated with immune checkpoint inhibitors.
    Khaddour, Karam
    Meeder, Natalie
    Kamel, Josette Mary
    Babwah, Amaara
    Nguyen, Ryan Huu-Tuan
    Wang, Heidy
    Liu, Li C.
    Feldman, Lawrence Eric
    Jain, Shikha
    Weinberg, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18731 - E18731
  • [22] OUTCOMES AND TOXICITY PROFILE OF PATIENTS WITH PRIMARY CARDIAC TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS <ICI>
    Abou Alaiwi, Sarah
    Nassar, Amin
    Zarif, Talal
    Macaron, Walid
    Denu, Ryan
    Freeman, Dory
    Abdel-Wahab, Noha
    El-Am, Edward
    Al-Hader, Ahmad
    Malvar, Carmel
    McKay, Rana
    Padera, Robert
    Neilan, Tomas G.
    Choueiri, Toni
    Naqash, Abdul-Rafeh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2351 - 2351
  • [23] Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data
    Calvo, Virginia
    Fernandez, Marta Andres
    Collazo-Lorduy, Ana
    Franco, Fernando
    Nunez, Beatriz
    Provencio, Mariano
    LUNG CANCER MANAGEMENT, 2021, 10 (04)
  • [24] Efficacy and safety of immune checkpoint inhibitors in older HCC patients: A real-world study
    Cheng, J.
    Chen, B.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S338 - S338
  • [25] The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
    Meyers, Daniel E.
    Stukalin, Igor
    Vallerand, Isabelle A.
    Lewinson, Ryan T.
    Suo, Aleksi
    Dean, Michelle
    North, Scott
    Pabani, Aliyah
    Cheng, Tina
    Heng, Daniel Y. C.
    Bebb, D. Gwyn
    Morris, Don G.
    CANCERS, 2019, 11 (11)
  • [26] Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).
    Florou, Vaia
    Floudas, Charalampos S.
    Maoz, Asaf
    Naqash, Abdul Rafeh
    Hildebrand, Gregory
    Sokol, Ethan
    Frampton, Garrett M.
    Puri, Sonam
    Swami, Umang
    Wilky, Breelyn A.
    Hosein, Peter Joel
    Trent, Jonathan C.
    Lopes, Gilberto
    Park, Wungki
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
    Assie, Jean-Baptiste
    Crepin, Florian
    Grolleau, Emmanuel
    Canellas, Anthony
    Geier, Margaux
    Grebert-Manuardi, Aude
    Akkache, Nabila
    Renault, Aldo
    Hauss, Pierre-Alexandre
    Sabatini, Marielle
    Bonnefoy, Valentine
    Cortot, Alexis
    Wislez, Marie
    Gauvain, Clement
    Chouaid, Christos
    Scherpereel, Arnaud
    Monnet, Isabelle
    CANCERS, 2022, 14 (06)
  • [28] Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with renal or hepatic dysfunction (dysf): Real-world patient characteristics and outcomes.
    Spillane, Susan
    Abernethy, Amy Pickar
    Brown, Nicholas R.
    Freedman, Andrew N.
    Lenis, David
    Maignan, Kathleen
    Mariotto, Angela
    Miksad, Rebecca A.
    Torres, Aracelis Z.
    Sharon, Elad
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study
    Delombaerde, D. L.
    Oeste, C. L.
    Verbiest, A. T. L.
    Tack, L.
    Croes, L.
    Bassez, I.
    Hens, D. F. E.
    Franssen, C.
    Debruyne, P. R.
    Prenen, H.
    De Sutter, J.
    Vulsteke, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S700 - S700
  • [30] Effect of type of antibiotics (Abx) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting
    Hobeika, Charbel
    Dawsey, Scott
    Patgunarajah, Ubenthira
    Lynn, David
    Pramod, Nikhil
    Wei, Wei
    Nair, Monica
    Maroli, Kimberly
    Martin, Allison
    Ornstein, Moshe Chaim
    Wee, Christopher Eing
    Gilligan, Timothy D.
    Nizam, Amanda
    Bonham, Amanda
    Mian, Omar Y.
    Pavicic, Paul G.
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 640 - 640
12345